GSK's RSV Vaccine Bags European Recommendation for Expanded Use

MT Newswires · 2d ago
02:34 AM EST, 12/12/2025 (MT Newswires) -- GSK (GSK.L) said Friday the European Medicines Agency's Committee for Medicinal Products for Human Use recommended the use of its Arexvy vaccine for adjuvanted recombinant respiratory syncytial virus, or RSV, in adults above 18 years of age. The London-listed drugmaker expects to secure the marketing authorization for the expanded indication of the vaccine from the European Commission in February 2026. Currently, Arexvy is approved in Europe for RSV patients 50 years and above.